Professional Documents
Culture Documents
Expended
Account Funder Start End Award Name Award including Balance Expended
Date Date commitments %
P10348 BMGF II 01/10/2006 31/12/2012 Integrated Health package £5,306,706 £5,243,704 £63,002 99%
P34831 DFID 01/10/2010 01/03/2016 NTD Treatment 8 countries £10,537,440 £7,336,731 £3,200,709 70%
Schistosomiasis and STH in
P36980 Burundi 01/06/2011 01/05/2014 Burundi £1,040,000 £768,897 £271,103 74%
Rwanda Phase II
P41895 END fund 01/03/2012 01/02/2015 programme £355,441 £340,647 £14,794 96%
TOTAL IMPLEMENTATION GRANTS £17,239,587 £13,689,979 £3,549,608 79%
SCI Account summary
2 OF 3 – Operational research
P10099 IC Trust 01/11/2006 N/A SCI Activities £362,883 £341,749 £21,134 94%
TOTAL UNRESTRICTED
FUNDS £2,831,192 £1,249,844 £1,581,348 44%
Implementation activities
Gates 36202 award
Gates (#36202). Core funding for SCI (since 2006) and the
evaluation of integrated control of Neglected Tropical
Diseases in Africa
If approved the new target will be over 200 million treatments in the existing 8
countries plus new programmes in Ethiopia and DRC
Implementation activities
Burundi & Rwanda, Schisto & STH
Burundi
Funding is in place to continue the national treatment campaigns in
Burundi for the next 3 years.
Rwanda
Funding is in place to continue the national treatment campaigns in
Rwanda for the next 3 years from the ENDFUND
Burundi Rwanda
Operational Research
SCI - SCORE – at University of Georgia (funded by Gates)
Research subcontracts have been executed with RISEAL Niger and Catholic University
of Mozambique
Total Anticipated SCORE funds 2010 to 2015 - US$1.245 million.
Initial 3 year budget funding originally agreed, the final 2 year extensions for
both countries are currently being finalised with SCORE.
Operational research
SCI - SCORE – budget v actual cost, as 31 May 2013
Operational Research
SCI – Gates, Control of Cysticercosis in sub Saharan Africa
SCI (10% total budget) provide lead management function and M&E expertise.
Operational Research
SCI – Gates, Control of Cysticercosis in sub Saharan Africa
• Imperial College has provided SCI with another account ( L24009 ) specifically for private
donations received direct to IC. To date some £2.26 million of unrestricted private donations
have been received into this account since it was set-up in Feb 2012. SCI claims Gift Aid
where allowable.
• These unrestricted funds have been used mainly for small scale interventions or “seed
money” in emerging countries e.g. Mozambique, Mauritania, Niger, Senegal & Cote D’Ivoire.
In addition, £500,000 has been ring-fenced for activity commitments in Ethiopia.
•END fund – Yemen, SCI have been awarded a grant for $150,000 for 2013 to support the
national Mass Drug Administration program in Yemen
• VITOL – have awarded SCI $130,000 for Cote D'Ivoire, integrated mapping & ICT activities.
•NTDs were highlighted on Red Nose Day in March 2013, and so Comic Relief may award their
first ever grant to control NTDs
•SCI has assisted Sightsavers win a £10 million award from DFID for NTD control in Northern
Nigeria.
•SCI is also assisting Sightsavers with work in mapping schisto and STH in N. Nigeria
Publicity and advocacy
• SCI has so far retained its position as a top rated charity by “Giving what we can”
www.givingwhatwecan.org
• SCI is one of the top three international charities recommended by
www.givewell.org in USA (they review their recommendation annually)
• These recommendations have highlighted SCI internationally, illustrated financial
transparency and led to increased donations. See recent Guardian article
• http://
www.guardian.co.uk/voluntary-sector-network/2013/jun/11/charity-evaluators-asse
ss-charities
• However it is imperative for the future of SCI that we continue to perform and be
transparent if we want to retain our recommendations from these evaluation sites.
Finally…
http://www3.imperial.ac.uk/schisto/newsroom/newsletter
http://www3.imperial.ac.uk/schisto/whatwedo/audiovideo
Thank you